A Comparative Study of the Healing Status by the Use of Alvogyl and Platelet-Rich Fibrin in the Treatment of Alveolar Osteitis: A Randomized Double-Blind Controlled Clinical Trial
Sponsor study identifier
interventional
102
1 country
1
Study Start
February 10, 2026
Actual (reported)Primary Completion
September 25, 2026
Actual (reported)Study Completion
October 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Alveolar osteitis, commonly known as dry socket, is a painful complication that can occur after tooth extraction, particularly following removal of a mandibular third molar. It occurs when normal healing of the extraction socket is disrupted and is commonly associated with significant pain and delayed healing. Alvogyl is a commonly used dressing for managing dry socket and can provide rapid pain relief. Platelet-rich fibrin (PRF) is a preparation made from the patient's own blood that contains platelets, white blood cells, fibrin, and growth factors that may promote tissue repair and wound healing. This randomized controlled clinical trial will compare Alvogyl and platelet-rich fibrin in patients diagnosed with alveolar osteitis following third molar extraction. A total of 102 eligible adult participants will be randomly assigned to receive either Alvogyl or PRF as treatment for the affected extraction socket. The study will compare the healing outcomes of the two treatments by assessing pain intensity and the number of exposed socket walls during follow-up. Pain will be assessed using a visual analogue scale, while socket healing will be evaluated clinically by recording the number of exposed socket walls. The study aims to determine whether PRF provides better healing outcomes than conventional Alvogyl treatment for alveolar osteitis. The findings may help clinicians select an effective treatment approach for reducing pain and promoting healing in patients with dry socket.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 10, 2026
Actual (reported)August 24, 2026
Actual (reported)August 27, 2026
Actual (reported)September 25, 2026
Actual (reported)October 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Mean Pain Score
Pain intensity will be assessed using a 0-10 Visual Analogue Scale (VAS), where 0 indicates no pain and 10 indicates the worst possible pain. The mean VAS pain score on postoperative Days 1 and 3 will be compared between the Alvogyl and platelet-rich fibrin groups.
Postoperative Day 1 and 3
Mean Number of Socket Wall Exposures
The number of exposed socket walls will be assessed by clinical examination on postoperative Days 1 and 3. The mean number of socket wall exposures will be compared between the Alvogyl and platelet-rich fibrin groups to evaluate the healing status of the extraction socket.
Days 1 and 3
Participants diagnosed with alveolar osteitis will receive standard socket irrigation with warm saline and debridement, followed by placement of Alvogyl into the extraction socket. The socket will be secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered.
Participants diagnosed with alveolar osteitis will receive autologous platelet-rich fibrin (PRF). Ten millilitres of venous blood will be collected and centrifuged without anticoagulant to prepare a PRF membrane. Following standard socket irrigation and debridement with warm saline, the PRF membrane will be placed into the extraction socket and secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered.
Alvogyl will be used as an intra-alveolar dressing for the treatment of alveolar osteitis. Following gentle irrigation of the extraction socket with warm saline and debridement, Alvogyl will be placed into the socket. The socket will then be secured with 3-0 silk sutures using a figure-of-eight technique to maintain the dressing in position. No topical or systemic antibiotics will be administered.
Autologous platelet-rich fibrin will be prepared from 10 mL of the participant's venous blood collected into two 5-mL tubes without anticoagulant. The blood will be centrifuged at 3000 rpm for 10 minutes. The resulting PRF layer will be separated and compressed between sterile saline-moistened gauze to form a membrane. Following standard socket irrigation and debridement with warm saline, the PRF membrane will be placed into the extraction socket and secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered.
CMH Lahore
Lahore, Pakistan
Asad A Chatha, BDS, FCPS
CMH Lahore Medical College and Institute of Dentistry
102 participants (actual enrollment reported by the registry).
First Submitted
August 24, 2026
First Posted
August 27, 2026
Study Start
February 10, 2026
Actual (reported)Photo Biomodulation Therapy for Alveolar Osteitis Recovery in Oral Contraceptive Users
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
September 25, 2026
Actual (reported)Study Completion
October 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 8, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: